Goldmann Sachs, gør det vi andre ikke må,
køber 3 stk. hver 10 sek.

"We have been in contact with the Orphazyme team. We are reassured about the NDA process with arimoclomol in NPC, just as we are reassured about our confidence in arimoclomol as a potential efficacious therapy in this underserved indication. We reiterate our probability rate of high 95% in NPC. Our Base Case at DKK 170 per share stands.

Regarding the US listing process, we hope to let it have its go and come back with a research note when we know the outcome. So far, the process seems to have put even further pressure on the stock, currently trading well below our Bear Case of DKK 95 per share. In the light of this, it is important for investors to adopt the broader picture; A potential US IPO, together with the current cash position and the potential sale of a Priority Review Voucher, could support the company's operations until cash positive. This is not to mention the equity story that investor buys into the stock; a late-stage orphan pipeline with multiple shots on goal."